GlassScriptPhysician profile
Shalene Badhan
NPI 1588846653
$16,684.20
in general payments reported to CMS, 2019-2025
39 companies · $2,681 in 2025
The $2,681 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,926 · 2020: $493 · 2021: $3,310 · 2022: $2,357 · 2023: $3,396 · 2024: $2,523 · 2025: $2,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,576 · Education: $23.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,575.58 |
| Education | $23.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,613.51 | 2019-2025 | Ofev, Cyltezo, Spevigo |
| Amgen INC. | $2,109.66 | 2019-2025 | Otezla, Krystexxa, Enbrel |
| Abbvie INC. | $1,297.30 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,089.84 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $839.16 | 2019-2025 | |
| Janssen Biotech, INC. | $799.75 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Astrazeneca Pharmaceuticals LP | $796.68 | 2021-2025 | Saphnelo |
| Pfizer INC. | $641.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $602.54 | 2019-2025 | Benlysta, Nucala |
| Radius Health, INC. | $599.95 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $541.82 | 2022-2023 | Krystexxa, Tepezza |
| Novo Nordisk INC | $532.24 | 2019-2023 | Wegovy |
| Aurinia Pharma U.S., INC. | $520.25 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $372.54 | 2022-2024 | Acthar |
| Lilly USA, LLC | $318.04 | 2019-2025 | Taltz |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $291.09 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $277.99 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $221.94 | 2022-2025 | Strensiq, Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $160.14 | 2024-2025 | Orencia |
| Merck Sharp & Dohme LLC | $129.28 | 2019-2020 | |
| Celgene Corporation | $119.87 | 2019 | |
| Genentech USA, INC. | $115.24 | 2019-2024 | Actemra |
| Medtronic Minimed, INC. | $101.72 | 2019 | |
| Organon LLC | $88.03 | 2022-2025 | Hadlima |
| Abbott Laboratories | $80.38 | 2019-2025 | Proclaim |
| Ibsa Pharma INC. | $75.63 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $49.98 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $42.47 | 2019 | |
| Octapharma USA, INC. | $36.85 | 2025 | Octagam Immune Globulin (Human), Panzyga |
| Sandoz INC. | $35.65 | 2023 | Hyrimoz |
| Pacira Therapeutics, INC. | $30.54 | 2019 | |
| Fresenius Kabi USA, LLC | $30.15 | 2025 | |
| Currax Pharmaceuticals LLC | $30.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.21 | 2022 | |
| Celltrion USA INC. | $15.70 | 2023 | Yuflyma |
| Kiniksa Pharmaceuticals International, Plc | $14.84 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $13.71 | 2019 | |
| Sobi, INC | $13.40 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $12.82 | 2023 | Zilretta, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalene Badhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.